Massive Bio

by Massive Bio  · Based in United States → — AI-Powered Oncology: Find the right cancer trials
Hematology Oncology
Website
Claim this tool
Is this the maker? Claim the company →

Overview

Massive Bio is a global precision oncology company that leverages artificial intelligence (AI) to connect cancer patients with suitable clinical trials and drug matching options. The platform utilizes advanced AI, including Natural Language Understanding (NLU) and Large Language Models (LLM), to analyze patients’ medical profiles, genomic data, and treatment histories. This enables rapid and accurate identification of relevant oncology and hematology clinical trials worldwide, significantly reducing the time it takes to match patients.

Beyond patient matching, Massive Bio’s solutions also support physicians by streamlining clinical trial referrals and offer services for pharmaceutical companies, Contract Research Organizations (CROs), and hospital networks to accelerate drug development and optimize trial enrollment. The company emphasizes a patient-centric approach, providing concierge services and operating globally in multiple languages.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered precision matching for clinical trials
  • Genomic and medical profile analysis
  • Real-time trial matching and eligibility notification
  • Physician oversight and validation of AI matches
  • Patient concierge and navigation services
  • Mobile application (SYNERGY-AI, Patient Connect)
  • Multi-agent neuro-symbolic AI platform (SYNERGY-AI, DLCTMS)
  • Natural Language Understanding (NLU) for medical records
  • Large Language Model (LLM) and Generative Pre-trained Text (GPT) co-pilots (Dr. Arturo AI, Ask Fiona AI)
  • AI-powered drug matching

Use Cases

  • Connecting cancer patients to suitable clinical trials
  • Streamlining clinical trial referrals for physicians
  • Accelerating drug development and patient enrollment for pharma/CROs
  • Generating real-world evidence (RWE) for research
  • Facilitating virtual tumor boards (VTB)
  • Identifying advanced treatment options for oncologists

What Physicians Need to Know

Patient Portal Integration
Massive Bio launched 'Patient Connect,' a free portal that uses AI to personalize access to cancer clinical trials. Patients can upload medical records, receive AI-powered trial matches, and communicate with coordinators. It also integrates features like FHIR-based digital check-in and identity verification, aligning with CMS interoperability frameworks.
Appointment Scheduling AI
Massive Bio offers 'concierge' support that assists patients with facilitating appointment scheduling with trial sites.
Multi-Language Patient Support
Massive Bio's services operate globally across multiple countries and languages, with reports indicating support for 11 to 18 languages.
Chronic Disease Management
Massive Bio focuses on oncology and hematology, utilizing AI to match cancer patients with suitable clinical trials. Their 'Reticulum Nexus' platform is designed to coordinate the full oncology journey, from initial contact to trial enrollment.
Medication Adherence Features
Massive Bio's strategic investment in Rivvi aims to build an end-to-end AI engagement infrastructure for healthcare, which includes supporting medication adherence and other complex-care workflows.
Patient Education Content
Massive Bio provides educational resources through its Patient Connect dashboard and its YouTube channel features videos explaining clinical trials, different cancer types, and patient stories.
Accessibility Compliance
Massive Bio states compliance with global data privacy standards such as GDPR and PIPEDA. They have also achieved SOC 2 Type 1 certification for their AI-enabled oncology technology platforms.
Physician Tip

Physicians can leverage Massive Bio's AI platform, such as the Deep Learning Clinical Trial Matching System (DLCTMS) and Trial Relay, to efficiently identify and match oncology and hematology patients to relevant clinical trials. The platform streamlines the pre-screening process, reducing the manual workload and enhancing referral and enrollment efficiency. The Virtual Tumor Board service, augmented by AI, provides an unbiased analysis of a patient's medical history and offers evidence-based treatment plans, which can be particularly beneficial for patients in rural areas or those seeking second opinions. The Patient Connect portal allows for secure data access and communication with patients, facilitating a more integrated approach to care.

Massive Bio has established key partnerships to expand its reach and capabilities. They are an OpenAI Select Partner, leveraging OpenAI's technology to convert complex clinical trial criteria into machine-readable formats for automated pre-screening. They also collaborate with organizations like FOMAT and PrecisCa to integrate their AI platform into physician networks and expand patient access to clinical trials. Their alignment with the CMS Health Tech Ecosystem and listing in the CMS Medicare App Library demonstrates their commitment to interoperability and connecting with a broader patient population. Additionally, Massive Bio has made a strategic investment in Rivvi to build an end-to-end AI engagement infrastructure for healthcare, which includes supporting medication adherence and other complex-care workflows.

Details

Category Patient Engagement & Education
Pricing Unknown
DeploymentCloud
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Unknown
Integrations
EHR Not specified
Specialties Hematology, Oncology

What the Web Says

Massive Bio is a digital health company that utilizes AI and physician expertise to connect cancer patients with suitable clinical trials globally. The company aims to overcome barriers like geography, financial constraints, and information asymmetry to improve access to cutting-edge therapies. They offer services like AI-powered clinical trial matching, personalized concierge support, and virtual tumor boards.

Overall: Mixed

Strengths

  • Uses AI to find matching trials, including those missed by other search methods.
  • Provides personalized reports outlining trial matches within 24 hours.
  • Connects patients directly with knowledgeable oncology nurses for free.
  • Offers flexibility across locations to find studies, aiding patients willing to travel.
  • Reports are accurate, thorough, and helpful, especially for those who haven't done extensive research.
  • Physicians refer patients to Massive Bio for support in finding clinical trials.

Limitations

  • Some physicians have described the company as 'terrible and unorganized'.
  • Employee reviews mention a lack of transparency, leadership, and support from executive management.
  • Employees report being belittled, gossiped about, and having no opportunities for growth.
  • One user questioned if the 'free resource' for AI analysis might lead to charges for results.
  • The company is not BBB accredited.

Based on reviews from: Reddit, OncoDaily, Massive Bio (via YouTube, website, and career pages), Asklepieia, Indeed.com, MobiHealthNews, BioSpace, GlobalData (via Pharmaceutical Technology), Better Business Bureau

Last updated: 2026-10-22

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Massive Bio

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

MobiHealthNews
Massive Bio named OpenAI Select Partner for oncology AI
Massive Bio has been named an OpenAI Select Partner, strengthening its ability to combine AI models with oncology expertise to improve clinical and research workflows. This partnership aims to move healthcare and life sciences organizations from pilots to measurable production workflows.
2026-08
Business Wire
Massive Bio Makes Inaugural Strategic Investment in Rivvi to Build an End-to-End AI Engagement Infrastructure for Healthcare
Massive Bio announced its first strategic investment in Rivvi, aiming to create an end-to-end AI engagement infrastructure for healthcare, enhancing patient outreach, prescreening, and support. This move expands Massive Bio's strategy to build core AI products and invest in complementary technologies.
2026-08
Business Wire
US Healthtech Company Massive Bio Expands Asia Footprint With South Korea Market Push
Massive Bio is expanding its presence in Asia, focusing on the South Korean market to connect cancer patients with clinical trials and support pharmaceutical companies in patient recruitment. The company has appointed Intralink to build relationships with hospitals, diagnostic laboratories, and oncologists in Seoul.
2026-09
Business Wire
TIME Recognizes Massive Bio Among the Top HealthTech Companies in AI and Data Analytics
Massive Bio has been included in TIME's World's Top HealthTech Companies 2026 in the AI & Data Analytics category, recognizing its role as an agentic AI and real-world data company advancing oncology drug development and access.
2026-09
BioSpace
Massive Bio and PrecisCa Announce Strategic Partnership to Expand Cancer Patient Access to Clinical Trials Across the U.S.
Massive Bio and PrecisCa have formed a strategic partnership to expand cancer patient access to clinical trials across the U.S., combining Massive Bio's AI-driven trial matching with PrecisCa's oncology provider network. This collaboration aims to increase patient identification and trial enrollment.
2026-09
BioSpace
Massive Bio Partners with TOUCH, The Black Breast Cancer Alliance and Navigating Trials to Expand Cancer Patients' Access to Clinical Trials
Massive Bio has partnered with TOUCH, The Black Breast Cancer Alliance, and Navigating Trials to integrate its AI-powered trial matching into their platforms, providing seamless access to personalized clinical trial options for cancer patients. This collaboration aims to reach underrepresented communities and improve access to clinical research.
2026-06
Clinical Trials Arena
Massive Bio, QC Healthcare join forces for cancer trial access
Massive Bio and QC Healthcare have partnered to enhance cancer patients' access to clinical trials, coordinated care, and telehealth services, aiming to address barriers to trial enrollment and provide continuous support throughout the treatment journey.
2026-07
ASCO
Effect of a novel artificial intelligence (AI) –enabled multi-trial matching system on patient matching using real-world data.
Massive Bio has developed an AI-enabled matching system that extracts structured clinical data from medical records and uses a recommendation system to match patients to clinical trials. A study involving 5,707 cancer patients demonstrated the system's effectiveness in retrospective matching analysis.
2023-06

Videos

Product demos, reviews, and walkthroughs for Massive Bio.

View all on YouTube

Frequently Asked Questions

Massive Bio utilizes an AI-powered platform to match cancer patients with suitable clinical trials, aiming to simplify the process for both patients and physicians. They offer 'Patient Connect,' a dashboard where patients can share medical records, communicate with their care team, view personalized trial results, and access educational resources. Additionally, Massive Bio provides 'concierge' support to assist patients in understanding eligibility, exploring financial aspects, and scheduling appointments, which helps to improve engagement and compliance.
While Massive Bio offers an AI-driven approach to clinical trial matching, alternatives include manual matching by clinical research teams, which can be time-consuming. Other companies also use AI for clinical trial recruitment, such as uMed and Alleviate Health. Physicians can also directly refer patients to trials within their own institutions or through established networks.
Massive Bio aims to provide affordable, evidence-based services to cancer patients. While they offer a free patient portal called 'Patient Connect' for accessing personalized trial matching reports, potential costs for extended services beyond basic matching should be confirmed directly with Massive Bio.
Massive Bio's platform, including 'TrialRelay' and 'Patient Connect,' is designed to expand access to clinical trials globally and across diverse populations. They partner with organizations like Just Worldwide to engage patients and advocacy communities at scale, including those typically harder to reach. However, the effectiveness of patient engagement can still be influenced by factors like digital literacy and access to technology.
Massive Bio's 'TrialRelay' platform is designed to fit seamlessly into everyday clinical workflows without requiring integration, offering a secure, cloud-based experience. They use AI to extract structured clinical data from medical records, which aids in matching patients to trials. The platform aims to simplify the referral process and reduce administrative burden for physicians.
Massive Bio employs security measures like encryption for patient health information. While they explicitly state they are not a HIPAA-covered entity, they indicate compliance with regulations such as GDPR and PIPEDA, and patients retain data rights including access and deletion.

Related Tools

Steer Health Care Gap Outreach
Steer Health
Patient Engagement & Education
Steer Health Care Gap Outreach identifies overdue services, prioritizes patient outreach, and automates follow-through across multiple communication channels to close care gaps.
Customized to organization size and agents deployed; no flat software subscription.
Xealth
Xealth
EMR / EHR Systems
Xealth is a digital health platform that enables healthcare providers to order and deliver personalized digital health content, apps, and services to patients directly from their EHR workflow.
EXF Care Gaps Solution
EXF Health
Clinical Decision Support & Reference
EXF Care Gaps solution provides AI-powered, FHIR-native care gap detection and summarization, integrated with Epic & Cerner EMRs, to improve patient outcomes and enhance quality scores.
MyChart (with Emmie AI assistant)
Epic Systems
EMR / EHR Systems
MyChart, developed by Epic Systems, is a leading patient portal that provides secure online access to medical records, test results, appointments, and health information for over 190 million patients worldwide. It now features Emmie, an AI assistant designed to simplify patient engagement and understanding of their care.
Customized
Symptom Checker (by AppCatalyst)
AppCatalyst
Patient Engagement & Education
Symptom Checker by AppCatalyst provides digital triage based on clinical protocols used by physicians and nurses, guiding patients to appropriate care levels and connecting them with providers. It helps users make informed decisions about their health, offering self-care advice for minor issues and directing them to suitable care when needed.
Syntra AI
Syntra AI
Medical Phone & Communication
Syntra AI is an all-in-one AI platform that automates patient bookings, communication, and administrative tasks for healthcare providers, integrating with major EHRs and ensuring HIPAA compliance.

See all Patient Engagement & Education tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-22 | First Added: 2026-04-22

Investors who backed Massive Bio

Funded through the company that built this tool.

Revo Capital
VC AI T2
Istanbul, Turkey
$1M-$5M
Revo Capital is Istanbul’s largest VC firm, operating around $188M in AUM across multiple funds with Fund II closing at EUR90M and…
AI/ML in Healthcare Diagnostics
AI Tool Finder
AI-powered search. Results may not be comprehensive.